RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA

被引：0
|
作者：
Lyubov, E. [1 ]
Dzhatdoeva, A. [2 ]
Zhao, Z. [3 ]
Cain, J. [4 ]
机构：
[1] Moscow Inst Psychiat, Moscow, Russia
[2] Janssen Cilag Russia, Moscow, Russia
[3] J&J Worldwide Hlth Econ & Pricing, Raritan, NJ USA
[4] Janssen Pharmaceut, B-2340 Beerse, Belgium
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66903-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A579 / A580
页数：2
相关论文
共 50 条
  • [31] Reduction in suicidal ideation and violent behaviour after six months of treatment with long acting risperidone in patients enrolled in the electronic schizophrenia adherence treatment registry (e-STAR)
    Hustig, H.
    Peuskens, J.
    Olivares, J.
    Povey, M.
    Jacobs, A.
    VALUE IN HEALTH, 2006, 9 (06) : A320 - A320
  • [32] Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection
    Chang, Chen-Lin
    Tzeng, Dong-Sheng
    Lung, For-Wey
    PSYCHIATRY RESEARCH, 2010, 180 (01) : 16 - 19
  • [33] Reduced hospitalisation in patients with schizophrenia initiated with risperidone long-acting injection (LAI): 3 month follow-up from the e-STAR database
    Naber, D
    Hustig, H
    Rosillon, D
    Wetterberg, L
    Caleo, S
    Ingham, M
    Eriksson, B
    Jacobs, A
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S124 - S125
  • [34] The electronic schizophrenia treatment adherence registry - E-STAR: An electronic registry to evaluate outcomes data in patients with schizophrenia/schizoaffective disorder
    Farmer, D
    Claerhout, B
    Mehnert, A
    Ingham, M
    Jacobs, A
    VALUE IN HEALTH, 2004, 7 (06) : 778 - 778
  • [35] Remission in patients with schizophrenia treated with risperidone long-acting injection (FLAI): 12 month interim results from e-STAR project in Czech Republic and Slovakia
    Tuma, I
    Pecenak, J.
    Povey, M.
    Lam, A.
    VALUE IN HEALTH, 2007, 10 (06) : A291 - A291
  • [36] Improvement in personal and social functioning in schizophrenia patients treated with risperidone long acting injection): 6-month results from E-star
    Pecenak, J.
    Tuma, I
    De groot-stam, E.
    Eriksson, L.
    Bork, B.
    Ligate, L.
    Povey, M.
    Lam, A.
    Trakas, K.
    Zhao, Z.
    VALUE IN HEALTH, 2008, 11 (03) : A127 - A127
  • [37] Risperidone long-acting injection (RLAI)-related sexual dysfunction in outpatients with schizophrenia
    Grosic, V.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 93 - 93
  • [38] The electronic schizophrenia treatment adherence registry-e-STAR. Results from Romania
    Miclutia, I. V.
    Podea, D. M.
    Damian, L.
    Craciun, I. D.
    Ciungu, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 148 - 148
  • [39] Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
    Apiquian, Rogelio
    Cordoba, Rodrigo
    Louza, Mario
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 19 - 26
  • [40] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
12345